Quick Answer
Inmune Bio, Inc. reported Net Income of -$45.93 million for fiscal year 2025.
Inmune Bio, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$45.93M | -9.2% |
| 2024 | -$42.08M | -40.2% |
| 2023 | -$30.01M | -9.9% |
| 2022 | -$27.30M | +10.0% |
| 2021 | -$30.34M | -150.8% |
| 2020 | -$12.10M | -57.6% |
| 2019 | -$7.68M | +38.3% |
| 2018 | -$12.44M | -1396.1% |
| 2017 | -$831.5K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.47M | +46.5% | +73.5% |
| June 30, 2025 | -$24.46M | -151.0% | -151.1% |
| March 31, 2025 | -$9.74M | +11.7% | +19.5% |
| September 30, 2024 | -$12.09M | -41.2% | -24.1% |
| June 30, 2024 | -$9.75M | -49.9% | +11.6% |
| March 31, 2024 | -$11.03M | -68.7% | -28.8% |
| September 30, 2023 | -$8.56M | -10.8% | -31.7% |
| June 30, 2023 | -$6.50M | +4.9% | +0.5% |
- Inmune Bio, Inc. showed a decrease of -9.2% in Net Income compared to the prior fiscal year.
- Over the 2017–2025 period, Inmune Bio, Inc.’s net income has declined by 5424.2% (from -$831.5 thousand to -$45.93 million).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: